# IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

> **NCT07138222** · — · RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 80 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07138222
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138222, "IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07138222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*